Rfg Advisory, LLC Incyte Corp Transaction History

Rfg Advisory, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 25, 2024	BUY	$52.16 - $64.19 $171,345 - $210,864	3,285 New	3,285 $206,000
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $5,777 - $7,233	-86 Reduced 2.92%	2,864 $230,000
Q3 2022 Nov 10, 2022	SELL	$66.18 - $82.86 $6,618 - $8,286	-100 Reduced 3.28%	2,950 $226,000
Q4 2021 Feb 02, 2022	BUY	$63.34 - $74.11 $193,187 - $226,035	3,050 New	3,050 $224,000
Q3 2021 Oct 19, 2021	SELL	$68.67 - $84.02 $181,975 - $222,653	-2,650 Closed	0 $0
Q2 2021 Jul 29, 2021	SELL	$79.87 - $87.53 $7,987 - $8,753	-100 Reduced 3.64%	2,650 $223,000
Q1 2021 Apr 19, 2021	BUY	$76.02 - $100.5 $380 - $502	5 Added 0.18%	2,750 $223,000
Q4 2020 Feb 02, 2021	SELL	$80.74 - $97.7 $2,825 - $3,419	-35 Reduced 1.26%	2,745 $258,000
Q1 2020 Apr 17, 2020	BUY	$63.18 - $85.97 $175,640 - $238,996	2,780 New	2,780 $204,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Rfg Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Rfg Advisory, LLC with notifications on news.